Results 161 to 170 of about 180,170 (299)

Orbital Plasmacytoma as Initial Presentation of Multiple Myeloma. [PDF]

Cureus
Rodríguez Garcés KN, Picón Barrón MF, Gámez L, Gomez-Alvarez U, Licea Moreno CA.   +4 more
europepmc   +1 more source

Unusual Cutaneous and Lymphatic Findings in an Adult Patient

JEADV Clinical Practice, EarlyView.
Sarah Preis, Mara Hubbuch, Susanne Annette Steimle‐Grauer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Mathematical modeling and analysis for multiple myeloma treatment [PDF]

Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow, where abnormal plasma cells overproduce a harmful antibody, M protein, leading to conditions such as bone lesions, renal dysfunction, and hypercalcemia. Although incurable, controlling
Watt, Kenton
core   +1 more source

Synchronous Presentation of Chronic Myelomonocytic Leukemia and Multiple Myeloma in a Treatment-Naïve Patient. [PDF]

Case Rep Hematol
Sweileh MW, Qamhia N, Batta A, Asaad H, Odeh RY, Swaileh M.   +5 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Evolution of multiple myeloma from a genomic perspective. [PDF]

Blood
Maura F, Samur M, Munshi N.
europepmc   +1 more source

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

CD70-targeted platform for diagnosing and treating multiple myeloma. [PDF]

J Immunother Cancer
Li J, Yan H, Wang X, Zhang Y, Chen P, Feng J, Zhang R, Li Z, Huang Z, Xu C, Ma N, Lin X, Zhao M, Zhu W, Peng Q, Xie S, Wei W, Dong M.   +17 more
europepmc   +1 more source

Real‐World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective case series evaluated all patients treated with daratumumab between 2018 and 2023 across two regional hospitals in Australia. Fifty‐two patients were included with a median age of 74. Median progression‐free survival (PFS) was 13 months and overall survival (OS) was 27 months, with an overall response rate was 35%.
Benjamin Reardon, Ian Kerridge, Tasman Armytage   +2 more
wiley   +1 more source